Table 1.
Clinical baseline of all 577 BLCA patients from TCGA cohort and GSE13507
| Variables | Training group (n=412) | Validation group (n=165) | Entire group (n=577) |
|---|---|---|---|
| Status | |||
| Alive | |||
| Dead | 156 (38.5) | 69 (41.8) | 225 (43.3) |
| Age | 68±10.57 | 65.18±11.97 | 67.19±11.06 |
| Gender | |||
| Female | 106 (26.2) | 30 (18.2) | 136 (23.9) |
| Male | 299 (73.8) | 135 (81.8) | 434 (76.1) |
| Race | |||
| White | 334 (82.5) | NA | NA |
| Asian | 43 (10.6) | NA | NA |
| Black or African | 28 (6.9) | NA | NA |
| AJCC-T | |||
| T0/Ta | 1 (0.2) | 24 (14.5) | 25 (4.4) |
| T1 | 3 (0.8) | 80 (48.5) | 83 (14.6) |
| T2 | 117 (28.9) | 31 (18.8) | 148 (25.9) |
| T3 | 193 (47.7) | 9 (5.5) | 212 (37.2) |
| T4 | 58 (14.3) | 11 (6.7) | 69 (12.1) |
| unknown | 33 (8.1) | 0 (0.0) | 33 (5.8) |
| AJCC-N | |||
| N0 | 235 (58.0) | 149 (90.3) | 384 (67.4) |
| N1 | 46 (11.4) | 8 (4.9) | 54 (9.5) |
| N2 | 75 (18.5) | 6 (3.6) | 81 (14.2) |
| N3 | 7 (1.7) | 1 (0.6) | 8 (1.4) |
| unknown | 42 (10.4) | 1 (0.6) | 43 (7.5) |
| AJCC-M | |||
| M0 | 195 (48.1) | 158 (95.8) | 353 (61.9) |
| M1 | 11 (2.7) | 7 (4.2) | 18 (3.2) |
| Mx | 199 (49.2) | NA | NA |
| Pathologic stage | |||
| I & II | 130 (32.1) | NA | NA |
| III & IV | 273 (67.4) | NA | NA |
| unknown | 2 (0.5) | NA | NA |
| Tumor grade | |||
| G1/G2 | 20 (5.0) | 105 (63.6) | 125 (21.9) |
| G3/G4 | 382 (94.3) | 60 (36.4) | 442 (77.6) |
| unknown | 3 (0.7) | NA | NA |
| TIICS level | |||
| Low | 203 (50.1) | 82 (50.0) | 285 (50.0) |
| High | 202 (49.9) | 83 (50.0) | 285 (50.0) |